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Abstract
Tumour-induced osteomalacia (TIO) is a rare paraneoplastic syndrome characterised by severe hypophosphataemia
and osteomalacia, with renal phosphate wasting that occurs in association with tumour. The epidemiology likewise
aetiology is not known. The clinical presentation of TIO includes bone fractures, bone and muscular pains, and
sometimes height and weight loss. TIO may be associated with mesenchymal tumours which may be benign or
malignant in rare cases. Mesenchymal tumour itself may be related to fibroblast growth factor 23 (FGF23), which is
responsible for hypophosphataemia and phosphaturia occurring in this paraneoplastic syndrome.
Hypophosphataemia, phosphaturia and elevated alkaline phosphatase are the main laboratory readings that may
lead to more precise investigations and better diagnosis. Finding the tumour can be a major diagnostic challenge
and may involve total body magnetic resonance imaging, computed tomography and scintigraphy using
radiolabelled somatostatin analogue. The treatment of choice for TIO is resection of a tumour with a wide margin
to insure complete tumour removal, as recurrences of these tumours have been reported. We provide here an
overview on the current available TIO case reports and review the best practices that may lead to earlier
recognition of TIO and the subsequent treatment thereof, even though biochemical background and the long-term
prognosis of the disease are not well understood. This review also includes a 4-year-long history of a patient that
featured muscular pains, weakness and multiple stress fractures localised in the hips and vertebra with subsequent
recovery after tumour resection. Because the occurrence of such a condition is rare, it may take years to correctly
diagnose the disease, as is reported in this case report.
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Background
Tumour-induced osteomalacia (TIO) is a rare paraneo-
plastic syndrome clinical presentation of which includes
bone fractures, bone and muscular pains, and sometimes
loss of height and even weight. Weight loss is unusual,
but sometimes observed, and could be explained by gen-
eral debilitated state of the patient with consequent poor
nutrient intake and loss of muscle mass [1, 2]. Most of
them are believed to be benign, although cases judged to
be histopathologically malignant have been also described
[3–6]. Mesenchymal tumour itself may be related to fibro-
blast growth factor 23 (FGF23), which is responsible for
hypophosphataemia and phosphaturia occurring in this
paraneoplastic syndrome. Hypophosphataemia, phospha-
turia and elevated alkaline phosphatase are the main
laboratory readings that may lead to more precise investi-
gations and better diagnosis. Although several hundreds
of cases have been reported since 1947 when McCance et
al. described the first TIO case [7], majority of clinicians,
radiologists and pathologists are not aware of this rare
disease with only several cases described in rheumatology
practice [5, 6, 8–14]. We provide an overview of the
current literature available on TIO case reports and review
the best practice for the diagnosis and treatment. We also
present here a 4-year-long case study of a patient who was
eventually diagnosed with TIO. We report the initial
presentation of the disease and the steps leading to
TIO diagnosis.
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Disease name and definition
TIO is characterised by severe hypophosphataemia and
osteomalacia, with renal phosphate wasting that occurs
in association with tumour. TIO also is called oncogenic
hypophosphatemic osteomalacia (M83.8) and appears in
the portal for rare diseases and orphan drugs under that
name (ORPHA352540). It was first described in 1947 by
Robert McCance, who reported a patient with pain,
weakness, gait abnormalities, and low phosphorus levels.
The patient was treated with high doses of vitamin D, but
the symptoms did not completely resolve until a tumour
in femur bone was removed [7].
The first person to clearly recognise that the disease
was the result of a “rachitogenic” substance was Andrea
Prader. In 1959, he described an 11 1/2-year-old girl
who developed severe rickets over the course of a year.
Evaluation showed decreased tubular phosphate reabsorp-
tion but otherwise normal kidney function. A tumour,
classified as a giant cell granuloma, was identified in a rib
and removed resulting in healing of rickets [15].
Epidemiology
The prevalence of the disease is not known. Since the
association between phosphate reabsorption and tumour
was first made, more than 300 cases of TIO have been
reported in the literature [16].
Pathogenesis
The first evidence of a circulating factor that could cause
phosphate wasting in phosphaturic disorders such as
TIO was demonstrated in a set of experiments in mice
by Meyer et al. and Nesbitt et al. [17, 18]. The first evi-
dence to support this concept in humans was the experi-
ment by Miyauchi et al. in which a tumour removed from
a patient and transplanted into nude mice caused hypo-
phosphatemia [19].
FGF23 was first identified as the phosphaturic substance
when mutations in FGF23 were linked to autosomal-
dominant hypophosphatemic rickets (ADHR) [20, 21].
Soon after that, elevations in serum FGF23 were found in
TIO and it was shown that FGF23 binds to target prox-
imal tubule cells via FGF receptor and inhibits renal phos-
phate reabsorption [21]. The primary transport protein
responsible for phosphate reabsorption in the kidney is
the type II sodium-phosphate co-transporters (NaPi-IIa
and NaPi-IIc) localised in the proximal tubule. High
circulating FGF-23 levels reduce the expression of the
co-transporters, leading to renal phosphate wasting
[16, 22–24]. FGF23 is also a regulatory hormone for
1.25-vitamin D and leads to a decreased concentration of
the vitamin in blood [25].
Excessive FGF23 action causes several hypophosphate-
mic diseases, including TIO, X-linked hypophosphatemic
rickets (XLHR), autosomal dominant and recessive hypo-
phosphatemic rickets (ADHR and ARHR) [26–28]. Under
physiological conditions, FGF23 is secreted predominantly
by bone and undergoes degradation by proteolytic en-
zymes [27]. By contrast, tumours secrete FGF23 to con-
centrations that are several hundred-fold higher than
normal levels, leading to dysregulation of FGF23 degrad-
ation pathway [29].
Histopathology
The tumours associated with TIO are usually small and
mesenchymal in origin [30]. The prototypical phosphatu-
ric mesenchymal tumour (mixed connective tissue vari-
ant) contains neoplastic cells that are spindled to stellate
in shape, normochromatic with small nuclei and indistinct
nucleoli. The nuclear grade is low, and mitotic activity is
usually absent or very low. The cells are typically embed-
ded within a myxoid or myxo-chondroid matrix with
“grungy” calcification that can resemble chondroid or
osteoid. Numerous osteoclast-like giant cells are a fre-
quent finding, and mature fat and even lamellar bone may
also be seen. A prominent feature of these tumours is an
elaborate intrinsic microvasculature with an admixture of
vessel size and vascular pattern [3]. The most common
diagnosis for these tumours has been hemangiopericy-
toma, but it has also included hemangioma, sarcomas,
ossifying fibromas, granulomas, giant cell tumours and
osteoblastomas.
Weidner in 1991 was the first to propose a classifica-
tion system based on the histological findings of 16 cases
of TIO and designated the tumours as phosphaturic
mesenchymal tumours [31]. TIO tumours can be further
subdivided into four categories: mixed connective tissue
variant (phosphaturic mesenchymal tumour mixed con-
nective tissue variant—PMTMCT), osteoblastoma-like
variant, non-ossifying fibroma-like variant, and ossifying
fibroma-like variant. The PMTMCT group is diagnosed
in 70–80 % of TIO cases and comprises neoplasias con-
taining primitive stromal cells, prominent vessel, and
osteoclast-like giant cells. PMTMCT tumours usually
occur in bones or soft tissues and are typically benign in
behaviour, but malignant variants have already been
described. Malignant examples show frankly sarcoma-
tous features, such as a high nuclear grade, high cellular-
ity, elevated mitotic activity and necrosis [3, 6, 22, 32].
The remaining three groups tend to occur in bones and
were also typically benign in behaviour.
When testing antigen expression, FGF23 is positive in
about 70 % of all the cases studied, and the proliferating
cells within the tumour are usually the source of FGF23
[3]. Somatostatin receptors have also been found to be
present in many TIO tumours [33–35].
While typically benign, malignant presentation and
metastases can occur [4, 5, 36]. While metastases are
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rare, infiltration of surrounding connective tissue is
typically present, which has significant implications for
surgical management and emphasises importance for wide
surgical margins to avoid persistence or reoccurrence.
Regardless of tumour morphology, the hallmark of the
diagnosis is the association of the tumour with the clinical
syndrome of TIO, which includes an elevation in plasma
FGF23 and its disappearance after tumour resection.
Clinical evaluation and diagnosis confirmation
Quoting Jiang et al. who reviewed 308 tumour-induced
osteomalacia cases reported in English literature between
1987 and 2011, about 46 % of reported cases of TIO have
occurred in females and 56 % in males, with a mean age
of 45.3 years when definitive diagnosis was made [37].
Within the reported cases TIO, tumours originate in
bones (40 %) and soft tissues (55 %). Most tumours are re-
ported to occur in the thigh and femur (22.7 %), craniofa-
cial region (20.7 %), ankle and foot (8.8 %), pelvis (8.2 %),
tibia and fibula (6.5 %) and arms (6.5 %). The less com-
mon locations are the vertebra, knee, hand, chest, abdo-
men, groin, perineum and gluteal region [3, 37, 38]. Some
tumours can even be located in organs such as the liver,
tongue, thyroid and lungs [1, 3, 4, 39]. A few patients
(2 %) are reported as having tumours in more than one
site, sometimes representing metastases [37].
Patients with TIO often present with many years of
symptoms before they are diagnosed. The symptoms
usually are nonspecific and often progressive. Common
complaints are bone pain, muscle weakness, reduced
height, and multiple fractures, primarily in the ribs, ver-
tebral bodies, and femoral neck [22, 37]. The patients
are often misdiagnosed with a variety of musculoskeletal,
rheumatologic diseases and sometimes even psychiatric
disorders [16, 40]. Hypophosphatemia caused by im-
paired renal phosphate reabsorption is the biochemical
hallmark of the disease. Additional laboratory tests can
be helpful in making the diagnosis of TIO. The typical
biochemical pattern of TIO includes normal or low
levels of 1,25-dihydroxyvitamin D, elevated levels of
alkaline phosphatase (reflecting osteoblast hyperactivity
and active bone remodelling) and normal circulating levels
of calcium and parathormone (PTH). In some cases, PTH
can be particularly high reflecting secondary hyperpara-
thyroidism, which is a normal response to low 1,25-
vitamin D caused by elevated FGF23 [22, 23, 41].
Differential diagnosis should always include renal
Fanconi’s syndrome—a disorder of the proximal renal
tubules, leading to impaired phosphate reabsorption and
hypophosphatemia. This syndrome may be genetic in
origin or it may occur as a complication of myeloma,
amyloidosis, or Sjogren’s syndrome. It can also occur
with certain medications or heavy metal poisoning. The
diagnosis can be confirmed by normal levels of FGF23
along with the presence of glycosuria, hypokalaemia, and
metabolic acidosis [2].
Once the diagnosis of an FGF23-dependent, phosphate
wasting disorder is made, a thorough history can aid in
excluding the genetic causes, such as XLHR, ADHR and
ARHR. Genetic testing can also be done.
Having narrowed the diagnosis to TIO, a careful phys-
ical examination should be performed, as the tumours
that cause TIO can sometimes be found in the subcuta-
neous tissue [42]. As tumours can arise in bone or soft
tissue, occur from head to toe and are typically very
small in size and slow-growing, locating these tumours
is often quite challenging. As a result, the time from
osteomalacia to identifying the associated tumour averages
a period of 5 years [43].
Finding the tumours can be a major diagnostic chal-
lenge and may involve total body magnetic resonance
imaging (MRI); as tumours can occur anywhere in the
body, it is important to scan the whole body, including
extremities, which is often excluded in routine nuclear
medicine imaging [44], computed tomography (CT), scin-
tigraphy using radiolabelled somatostatin analogue (such
as 99mTc-Tektrotyd) and positron emission tomography,
with computed tomography: fluorodeoxyglucose (18F-
FDG) PET/CT and galium (68Ga) DOTATATE PET/CT
and selective venous sampling for FGF23 [44–51].
A stepwise approach is advocated, first performing
functional tests. Tumours associated with osteomalacia
variably express five somatostatin receptors (SSTR1-5),
allowing SSTR-based functional imaging by somatostatin
analogue scintigraphy or positron emission tomography
[33, 46, 52, 53]. Octreotide is somatostatin analogue
used in treatment of some neuroendocrine tumours and
acromegaly. It is possible to radiolabel the somatostatin
analogue in an attempt to detect tumours that express
somatostatin receptors [38, 47, 52]. Octreotide scanning
is commonly performed with 111In-labelled pentatreo-
tide. Octreotide scintigraphy is successfully used to lo-
cate tumours in up to 95 % of patients with TIO [37]. It
may even be possible to use this technology therapeutic-
ally in radioimmunoguided surgery or labelling of
octreotide with a beta-emitting radionuclide [47]. Des-
pite this success, there are several limitations of this im-
aging technology. Inflammatory reactions or a fracture
will be associated with a false-positive scan. Somato-
statin analogues scintigraphy is also limited by planar
two-dimensional imaging and relatively poor spatial
resolution, which is particularly problematic given that
TIO tumours are often very small. Single-photon emis-
sion tomography (SPECT) or hybrid SPECT/CT enables
three-dimensional imaging and better tumour contrast
but is time-consuming and therefore limited to areas of
suspected abnormality rather than a whole body survey
[35]. Somatostatin analogue positron emission tomography
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can dramatically improve the spatial resolution and lesion
detectability [54].
Anatomic imaging (radiography, CT and MRI) should
be performed to confirm the location of the tumour
after suspicious lesions had been identified by functional
imaging [13]. High-resolution magnetic resonance im-
aging of the whole body is the currently proposed method
of choice to confirm the location of the tumour [41].
Despite all of the advances in imaging that are avail-
able today, tumour localization may not be successful. If
this is the case, imaging studies should be repeated every
1–2 years.
Treatment
The treatment of choice for TIO is resection of a tumour
with a wide margin to insure complete tumour removal, as
recurrences of these tumours have been reported [4, 9, 36].
Tumour removal is always curative, and following com-
plete resection of the tumour, the recovery and improve-
ment of the patients is relatively quick, FGF23 disappears
rapidly from the circulation, and serum phosphate returns
to normal by day 5 post operation [55]. Most patients feel
better within days to weeks of tumour removal. Bone heal-
ing starts immediately, but depending on the severity of
the disease, it may take up to a year for a more significant
clinical improvement to be seen.
In case of incompletely resected tumours, subsequent
radiotherapy can be used to avoid recurrence or metas-
tasis (41). Late recurrence due to metastatic disease is
rare but possible. This probably occurs in less than 5 %
of the patients with TIO [3, 36]. Lung is a common site
for metastasis. The course after metastasis is quite vari-
able, and survival of up to 30 years has been reported
[56]. There is no chemotherapeutic regimen with any
demonstrated efficacy in treating metastatic TIO. Radio-
frequency ablation (RFA) has been reported as a possible
treatment modality [14].
When the tumour cannot be localised or is not surgi-
cally resectable, medical therapy with phosphate supple-
mentation and calcitriol or alfacalcidol is used. Treatment
with octreotide is an alternative form of medical therapy
that may be considered. In one case report, phosphate
wasting and hypophosphatemia were corrected with
octreotide therapy; this effect was presumably mediated
by somatostatin receptor expression by the tumour,
which was demonstrated by octreotide scintigraphy [43].
However, not all patients respond to octreotide [33, 57].
Treatment with the calcium-sensing receptor agonist,
cinacalcet, could also be effective for the treatment of TIO
patients by inducing hypoparathyroidism and thus
increasing renal phosphate reabsorption [58].
Anti-FGF23 antibody is being studied as a novel ther-
apy for FGF23-related hypophosphatemic diseases [59].
Results of phase I study of single injection of humanized
anti-FGF23 antibody for adult patients with XLHR were
recently published. This antibody therapy may be useful
for patients with TIO [60, 61].
Prognosis
The prognosis depends on detecting the tumour and
possibility to remove it widely. The tumours when de-
tected are typically benign in most of the cases. The
symptoms disappear and the healing of the bones begin
after total removal of the tumour. Nevertheless, the
follow-up should be continued because the delayed me-
tastasis can occur as it was described in few cases.
Case report
A 48-year-old man was first seen by a rheumatologist in
the beginning of 2011 because of progressing weakness,
10 kg weight loss during the recent year, diminishing
height and muscular and bone pain in arms, lower back
and chest which severely limited his movements. The
patient felt unhealthy since 2009; however, his life his-
tory had no recorded health-related problems except for
rib fracture during a car accident in his childhood and
many years of smoking. His family history revealed that
his father died of pancreatic cancer, his brother died of
oncohematology condition and his mother lives with
oncohematological disease. At the time of investigation,
he was 180 cm tall (being 184 cm when healthy) and
weighted 73 kg (BMI = 22.5 kg/m2). Physical examin-
ation revealed scoliosis and kyphosis of the spine, overall
weakness, weakness in muscles and pain in both arms
when palpating. The laboratory investigations showed
no inflammation, and the only abnormality in serological
readings was elevated alkaline phosphatase—248 U/l
(normal values, 40–150) due to its bone-specific fraction
comprising 80.5 % (Table 1). The radiology of the spine
revealed compressive fracture in Th11–Th12, which was
confirmed by the following computed tomography (CT)
scan and magnetic resonance imaging (MRI) readings as
well. Bone mineral density was 0.840 g/cm2 indicating
osteopenia. Because of the family history, the patient
underwent urological examination and ultrasound of the
thyroid gland, liver, spleen and prostate. His lung CT
scan was inconspicuous with small atelectasis in lower
segments. He was also referred to a haematologist and
endocrinologist, but after examination, both myeloma and
parathyroid disease were excluded, although autoimmune
thyroiditis due to raised autoantibodies against thyroid
tissue was diagnosed. No treatment except for painkillers
was prescribed.
With continuing weight and height loss together with
bone and muscle pain, the patient was hospitalised at
the Department of Rheumatology for thorough exa-
mination in November 2011. The alkaline phosphatase
remained elevated and hypophosphatemia 0.48 mmol/l
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(normal values, 0.87–1.45) was documented for the first
time. The 24-h urine sample phosphaturia showed normal
phosphate clearance 26.5 mmol/24 h (normal values,
12.9–42.0 mmol/24 h) and subsequent phosphate readings
in urine were within normal values as well. Vitamin D
levels, calcium and ionised calcium readings were found
within the normal values: vitamin D being 78.4 nmol/l
(normal values, 75–100); calcium 2.25 mmol/l (normal
values, 2.15–2.50); and ionised calcium 1.12 mmol/l (nor-
mal values, 1.05–1.30); nevertheless, he used periodically
prescribed bone mineral supplements from the beginning
of disease. The radiology of spine showed a new com-
pressive fracture in the level Th7–Th8 in addition to the
old fracture, which was later confirmed by CT scan. Whole
body bone scintigraphy with 99mTc-MDP 550 MBq
showed increased focal uptake of a radiotracer in the left
shoulder and in the ribs on both sides due to osteoblastic
process and reduced uptake in right femoral on SPEC/CT
sclerotic bone lesion without tumour at that time or
Morbus Paget specificity (Fig. 1). At that time, undiffe-
rentiated bone structural changes (M85.9) were diagnosed
because of compressive fractures in spine, increased bone
specific fraction of alkaline phosphatase and no evidence
found for oncologic disease.
In February 2012, the avascular necrosis of both femur
heads with osteosclerotic locus in the right femur of
unknown origin was found by MRI. During routine
follow-up in 2013, additional compressions were found
in spine CT, now overtaking the segment from T5 to
T12. The bone density continued to diminish up to
0.76 g/cm2 in the hip and spine, and alkaline phosphatase
readings remained elevated. The antiosteoporotic treat-
ment was started at that time with ac. zolendronicum
(5 mg/100 ml) administered intravenously and repeated
after a year of interval but with no clinical or laboratory
improvement. It was discontinued and switched to oral
Fig. 1 a Whole body bone scintigraphy 99mTc-MDP. Moderate uptake in the right shoulder, on both sides of the ribs due to osteoblastic lesions.
Reduces radiotracer uptake in right femoral head (long arrow). b 99mTc-MDP SPECT/CT of the pelvis. Reduced radiotracer uptake in right femur
head, corresponding sclerotic lesion on CT (long arrow) (year 2011)
Table 1 The sequence of laboratory findings from the beginning of disease
2011 2012 2013 2014 2015
Sequence of analysis 1st 2nd 1st 2nd 1st 1st 2nd (1 year after hip arthroplasty)
Laboratory findings
Phosphate (0.87–1.45 mmol/l) 0.48 0.52 0.36 1.19
24 h urine sample phosphate (12.9–42.0 mmol/24 h) 26.49 17.97 %TPR = 90.52a
Calcium (2.15–2.50 mmol/l) 2.25 2.37 2.42 2.40 2.48
Ionised calcium (1.05–1.30 mmol/l) 1.12 1.16 1.30 1.09
Alkaline phosphatase (40–150 U/l) 248 274 310 257.25 297.7 319.19 279 85.97
25-OH vitamin D (75–100 nmol/l) 78.4 54.68 47.93 77.70 85.83 72.3 44.42
Parathyroid hormone (1.6–7.2 pmol/l) 6.07 8.10 19.9 12.01
FGF-23 26–110 U/l 589 104 (measured 3 months after
hip arthroplasty)
a%TPR = 90.52—calculated according to the formula: 100 × (1− ((urine phosphate/urine creatinine) × (serum creatinine/serum phosphate))). 100 × (1 − ((45.06/28.521) ×
(0.07/1.17))) and was found to be in normal range between 85 and 95 %. Numbers are entered in millimoles per liter
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bisphosphonate. Natrium risedronate was initially pre-
scribed in dosage of 35 mg once per week and subse-
quently increased to 35 mg per day but was discontinued
in the fall 2014 because of no effect.
During the time period of almost 4 years, the clinical
condition continued to worsen with a loss of height for
15 cm and weight for 20 kg from year 2011 now standing
for 165 cm height and 53 kg weight (BMI = 23.1 kg/m2),
permanent pain in chest and hips, progressing breathing
discomfort, muscular weakness, inability to bend below
knees and posture change (Fig. 2, photo taken in October
2014). Taking in account hypophosphatemia, elevated
alkaline phosphatase from the beginning of disease, com-
pressive fractures and avascular necrosis in femur heads,
the differential diagnosis was broadened to acquired
Fanconi’s syndrome, X-chromosome-linked hypophospha-
taemia and phosphaturic tumour-induced osteomalacia.
To rule out Fanconi’s syndrome, the heavy metals analysis
for copper, lead, cadmium and mercury were ordered and
were found to be in normal ranges: copper 15.7 μmol/l
(n, 11–22), lead 9.60 μg/l (n, 0–90), cadmium 0.8 μg/l
(n, 0–1.7) and mercury <1.0 μg/l (n, 0–5). Because of
disease manifestation in adulthood, no analysis for
FGF gene mutation was requested. FGF-23 readings
were found increased fivefold and being 589 U/l (normal
values, 26–110 U/l). The whole body scintigraphy with
somatostatin analogues 99mTc-tekrotyd 605 MBq re-
vealed intensive uptake of radiotracer in the right femoral
head, and SPECT/CT demonstrated uptake in sclerotic
bone lesion in the right femoral head—tumour intensively
Fig. 3 a 99mTc-Tektrotyd SPECT /CT of a pelvis. Focal, intensive radio tracer uptake in right femoral head (long arrow) and b corresponding
sclerotic lesion on CT (long arrow) (year 2014)
Fig. 2 a The posture before the right hip endoprosthesis operation and tumour extirpation. The patient has given the written consent for his
medical findings and photos to be published. b 99mTc-Tektrotyd whole body scintigraphy. Intensive, focal radiotracer uptake in right femur head
( red markers around) (year 2014)
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expressing somatostatin receptors (Fig. 3). For possible
multicentre tumour localization, the whole body CT was
ordered. CT indicated deformations in skeletal bones, rib-
bons, thoracic vertebrae and pelvic bone due to osteomal-
acia or stress fractures, and no signs of healing were
observed. CT also showed compressive fractures in Th3–
Th11 with pathologic kyphosis, stress fractures in both
femoral heads and osteosclerotic tumour in right femur
head (Fig. 4). No deformations were found in soft tissues,
parenchymal organs, lungs or lymph nodes.
With strong prediction of phosphaturic mesenchymal
tumour-induced osteomalacia, a tumour-removal sur-
gery was performed, and subsequently, removal of the
head and the neck of the right femur was required fol-
lowing total hip arthroplasty in October 2014. Surgical
specimen was presented by femur proximal head. Exam-
ination revealed ill-defined intramedullary grey tumour,
approximately 2 cm in diameter. Bone tissue was soft,
macroscopically intact by tumour and showed a broad
band of cartilage under articular surface. Histologic
examination of the specimen revealed a hypercellular
tumour composed of spindle-shaped cells in fibromyxoid
matrix, with a hemangiopericytoma-like pattern. Tumour
cells had clear to eosinophilic cytoplasm; nuclei were oval
or elongated, of monomorphic appearance and with no
signs of atypia. Mitotic figures were rare. Surrounding
bone trabeculae were irregular in size and shape with wide
osteoid seams and foci of hyaline cartilage, showing
enchondral ossification. The tumour cells were strongly
and diffusely positive with vimentin but exhibited no
reactivity with PanCK, SMA, CD34, CD10 and D2-40
(Fig. 5).
Fig. 5 Histologic examination of the specimen revealed a hypercellular tumour composed of spindle-shaped cells in fibromyxoid matrix, with a
hemangiopericytoma-like pattern (a). Tumour cells had clear to eosinophilic cytoplasm, nuclei were oval or elongated, of monomorphic appearance,
with no signs of atypia. Mitotic figures were rarely seen. Surrounding bone trabeculae were irregular in size and shape with wide osteoid seams and
foci of hyaline cartilage, showing enchondral ossification (b, c). The tumour cells were strongly and diffusely positive with vimentin (d) but exhibited
no reactivity with PanCK, SMA, CD34, CD10 and D2-40 (year 2014)
Fig. 4 Osteosclerotic tumour in the right femur head revealed
during the whole body computerised tomography (year 2014)
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The post operation period went without clinical com-
plications and after 3 months the levels of phosphorus,
alkaline phosphatase and FGF-23 were measured. Alka-
line phosphatase remained elevated 316 IU/l (40–150)
with bone fraction now standing at 57.7 % and FGF-23
returned to normal values 104 IU/l (26–110 IU/l). Three
months after surgical procedure, the body pain almost
disappeared and the weight increased up to 62 kg and
height up to 166 cm (BMI = 22.5 kg/m2). The alkaline
phosphatase returned to normal values 6 months after
tumour extirpation and remained within normal values
after 1 year of follow-up (Table 1). The phosphorus level
increased remarkably up to 1.51 mmol/l (normal range,
0.87–1.45) after 3 months and normalised within 1 year.
We have to admit that measuring 24-h urinary phos-
phate was not a proper phosphate balance measure
throughout the disease course. Without applying more
sophisticated methods, e.g. percent tubular reabsorption
of phosphate (%TRP) or tubular maximum for phos-
phate corrected for glomerular filtration rate (TmP/
GFR) as it is recommended [16], significant loss of phos-
phate was probably missed from the beginning of dis-
ease. Conventional radiography of the spine after 1 year
showed permanent and nonreversible spine deformation
due to the old compressions from Th3 to Th11 with no
evidence of new compression fractures (Fig. 6).
Conclusions
The diagnosis of TIO is a challenge under the best of
circumstances. TIO should be included in the differen-
tial diagnosis in patients with progressive weakness,
bone and muscle pain and multiple fractures. The diag-
nosis is commonly delayed for years due to the nonspe-
cific nature of the presenting symptoms, failure to
include determination of serum phosphorus levels in
blood chemistry testing and difficulty in identifying the
responsible tumour. The professional evaluation of
whole body images, including single-photon emission
tomography enables identification and better tumour
contrast which can be found in skeletal structures of
whatever region of the human body. FGF23 may be of
help to understand the underlying mechanisms of TIO
and a measurement to follow up the disease course.
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Fig. 6 Conventional radiography of the spine after 1 year after
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deformation due to the old compressions from Th3 to Th11 with no
evidence of new compression fractures (year 2015)
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